DDInter40 DDInter899
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Alefacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bleomycin
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibritumomab tiuxetan
Alefacept {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ibritumomab tiuxetan
Alefacept may lead to a major life threatening interaction when taken with Upadacitinib